Comparison of optical coherence tomography assessments in the comparison of age-related macular degeneration treatments trials.
暂无分享,去创建一个
Glenn J Jaffe | Cynthia A Toth | Gui-Shuang Ying | Maureen G Maguire | Francisco A Folgar | G. Ying | M. Maguire | F. Folgar | C. Toth | G. Jaffe | G. Ying
[1] Sumit Sharma,et al. Comparison of spectral-domain versus time-domain optical coherence tomography in management of age-related macular degeneration with ranibizumab. , 2009, Ophthalmology.
[2] Christian Ahlers,et al. Quantification of the therapeutic response of intraretinal, subretinal, and subpigment epithelial compartments in exudative AMD during anti-VEGF therapy. , 2011, Investigative ophthalmology & visual science.
[3] Ian C. Han,et al. Comparison of spectral- and time-domain optical coherence tomography for retinal thickness measurements in healthy and diseased eyes. , 2009, American journal of ophthalmology.
[4] Glenn J Jaffe,et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.
[5] C. Toth,et al. Reproducibility of Optical Coherence Tomography Image Grading During the Comparisons of Age-Related Macular Degeneration Treatments Trials (CATT) , 2012 .
[6] Changhuei Yang,et al. Sensitivity advantage of swept source and Fourier domain optical coherence tomography. , 2003, Optics express.
[7] Glenn J Jaffe,et al. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. , 2013, Ophthalmology.
[8] Glenn J Jaffe,et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. , 2013, Ophthalmology.
[9] Robert N Weinreb,et al. Comparison of macular thickness measurements between time domain and spectral domain optical coherence tomography. , 2008, Investigative ophthalmology & visual science.
[10] A. Feinstein,et al. High agreement but low kappa: I. The problems of two paradoxes. , 1990, Journal of clinical epidemiology.
[11] G. Ying,et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. , 2012, Ophthalmology.
[12] Joseph A Izatt,et al. CORRELATION OF PATHOLOGIC FEATURES IN SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY WITH CONVENTIONAL RETINAL STUDIES , 2008, Retina.
[13] A. Hendrickson,et al. A qualitative and quantitative analysis of the human fovea during development , 1986, Vision Research.
[14] Christian Simader,et al. Evaluation of optical coherence tomography findings in age-related macular degeneration: a reproducibility study of two independent reading centres , 2008, British Journal of Ophthalmology.
[15] G. Ying,et al. Petaloid Macular Edema and Outcomes in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT) , 2015 .
[16] C. Toth,et al. Optical coherence tomography reader agreement in neovascular age-related macular degeneration. , 2007, American journal of ophthalmology.
[17] A. Alm,et al. Is quantitative spectral‐domain superior to time‐domain optical coherence tomography (OCT) in eyes with age‐related macular degeneration? , 2012, Acta ophthalmologica.
[18] J. Duker,et al. Ultrahigh-resolution, high-speed, Fourier domain optical coherence tomography and methods for dispersion compensation. , 2004, Optics express.
[19] B. Bouma,et al. Improved signal-to-noise ratio in spectral-domain compared with time-domain optical coherence tomography. , 2003, Optics letters.
[20] G G Koch,et al. A general methodology for the analysis of experiments with repeated measurement of categorical data. , 1977, Biometrics.
[21] Sandra S Stinnett,et al. Optical coherence tomography grading reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials. , 2012, Ophthalmology.
[22] D. Browning. Interobserver variability in optical coherence tomography for macular edema. , 2004, American journal of ophthalmology.
[23] J. Caprioli,et al. Optical coherence tomography to detect and manage retinal disease and glaucoma. , 2004, American journal of ophthalmology.
[24] J. R. Landis,et al. The measurement of observer agreement for categorical data. , 1977, Biometrics.
[25] Joan W. Miller,et al. Reproducibility of retinal thickness measurements on normal and pathologic eyes by different optical coherence tomography instruments. , 2010, American journal of ophthalmology.
[26] Barry Cense,et al. Spectral domain optical coherence tomography: ultra-high speed, ultra-high resolution ophthalmic imaging. , 2005, Archives of ophthalmology.
[27] M. Shahidi,et al. Quantitative thickness measurement of retinal layers imaged by optical coherence tomography. , 2005, American journal of ophthalmology.
[28] J. Duker,et al. Optical coherence tomography of age-related macular degeneration and choroidal neovascularization. , 1996, Ophthalmology.
[29] F. Folgar,et al. Assessment of retinal morphology with spectral and time domain OCT in the phase III trials of enzymatic vitreolysis. , 2012, Investigative ophthalmology & visual science.
[30] Susanne Binder,et al. Repeatability and reproducibility of retinal thickness measurements by optical coherence tomography in age-related macular degeneration. , 2010, Ophthalmology.